Clearsight Advises Bionest Partners in its Acquisition by Accenture

Clearsight Advisors, Inc. (“Clearsight”) is pleased to share another successful transaction in its Healthcare and Life Sciences Practice. Clearsight served as exclusive financial advisor to Bionest Partners, Inc. (“Bionest” or the “Company”) in its acquisition by Accenture (NYSE: ACN).

Bionest is an industry-leading life sciences consulting firm focused on commercialization, go-to-market strategy, and launch execution services across pharma, biotech, medical device, and diagnostics. Founded in 2003 in Paris, Bionest’s team of consultants now spans across the US and Europe. The Company’s powerful combination of deep content knowledge and a collaborative approach bring key insights to its blue-chip pharma and biotech clients. Read more on the transaction here.

Melinda Kutzing, Ph.D., Managing Director at Bionest, commented, “Bionest was at a pivotal stage in our growth journey, so we sought an advisor who could understand the current market and our future goals. The Clearsight team delivered by providing valuable advice and guiding us through this novel process. The outlook is bright for Bionest, and we’re thankful to Clearsight for their help in achieving such a momentous goal.”

Tory Steel, Clearsight Director, added, “The life sciences M&A market has evolved considerably since 2020. Bionest’s first-class team and high-value service offering cut through a crowded market to earn its reputation as a respected player in the space. We look forward to watching the Bionest team continue to deliver innovative solutions to clients.”

Greg Treger, Managing Director and Head of the Healthcare and Life Sciences Practice at Clearsight, noted, “Bionest is an exceptional life sciences consultancy comprised of an incredibly knowledgeable and energetic team able to tackle the complexities of the go-to-market strategy in precision medicine, cell and gene therapy, and rare diseases. We are excited to see all that their talented team accomplishes in the future.”

The Clearsight deal team included Greg Treger, Tory Steel, Emily White, Jonathan Holland, Logan Flake, and June Jang.